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Blood pressure (BP) is significantly influenced by genetic factors; however, less than
3% of the BP variance has been accounted for by variants identified from genome-
wide association studies (GWAS) of primarily European-descent cohorts. Other genetic
influences, including gene-environment (GxE) interactions, may explain more of the
unexplained variance in BP. African Americans (AA) have a higher prevalence and earlier
age of onset of hypertension (HTN) as compared with European Americans (EA);
responses to anti-hypertensive drugs vary across race groups. To examine potential
interactions between the use of loop diuretics and HTN traits, we analyzed systolic (SBP)
and diastolic (DBP) blood BP from 1222 AA and 1231 EA participants in the Hypertension
Genetic Epidemiology Network (HyperGEN). Population-specific score tests were used
to test associations of SBP and DBP, using a panel of genotyped and imputed single
nucleotide polymorphisms (SNPs) for AA (2.9 million SNPs) and EA (2.3 million SNPs).
Several promising loci were identified through gene-loop diuretic interactions, although
no SNP reached genome-wide significance after adjustment for genomic inflation. In AA,
SNPs in or near the genes NUDT12, CHL1, GRIA1, CACNB2, and PYHIN1 were identified
for SBP, and SNPs near ID3 were identified for DBP. For EA, promising SNPs for SBP were
identified in ESR1 and for DBP in SPATS2L and EYA2. Among these SNPs, none were
common across phenotypes or population groups. Biologic plausibility exists for many of
the identified genes, suggesting that these are candidate genes for regulation of BP and/or
anti-hypertensive drug response. The lack of genome-wide significance is understandable
in this small study employing gene-drug interactions. These findings provide a set of
prioritized SNPs/candidate genes for future studies in HTN. Studies in more diversified
population samples may help identify previously missed variants.
Keywords: blood pressure, hypertension, loop diuretic, gene-drug interaction, genome-wide association, african
americans, european americans
INTRODUCTION
High blood pressure (BP) is the leading cause of death in the
United States, contributing to a wide spectrum of cardiovascu-
lar, cerebrovascular, and renal diseases (Chobanian et al., 2003).
In the United States, one in three adults has high BP, with a mor-
tality rate of 18.3 per 100,000 individuals annually. Public health
costs due to hypertension (HTN) and its sequelae are approx-
imately $51 billion per year (Roger et al., 2012). Among US
adults, the age-adjusted prevalence of HTN is 42.5% in African
Americans (AA), 26.1% for Mexican Americans, and 29.1% for
Non-Hispanic European Americans (EA). This disparity is greater
for HTN than for other cardiovascular risk factors including
dyslipidemia and diabetes (Fryar et al., 2010). In past years,
genetic studies of HTN and BP were largely limited to cohorts
of European ancestry. However, it is still unknown the extent to
which findings discovered in a European-based population are
applicable to other race/ethnic groups (Rosenberg et al., 2010).
Although a moderate portion of the between-individual
variance of HTN-related traits are explained by genetic fac-
tors, identifying the loci responsible for BP regulation has
remained frustrating. The heritability of BP ranges from about
30–45% in pedigree data to as high as 60% in twin studies
(Biron et al., 1976; Feinleib et al., 1977; Rotimi et al., 1999;
Snieder et al., 2003; Hottenga et al., 2005; Mitchell et al.,
2005). Heritability estimates vary depending on the specific
trait (for example, systolic BP, diastolic BP, and HTN) and the
means by which these traits are ascertained. Heritability esti-
mates derived from non-European cohorts are similar to or
higher than in European cohorts (Rotimi et al., 1999; Bochud
et al., 2005; Zhang et al., 2009). Yet despite the substantial
estimated heritability and sample size in excess of 200,000
subjects, common variants identified by genome-wide associ-
ation (GWA) studies explain less than 3% of inter-individual
BP variation (International Consortium for BP GWAS et al.,
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2011). While the reasons for this “missing heritability” have
been explored in detail elsewhere (Manolio et al., 2009; Zhang
et al., 2010), it is important to consider that the majority
of GWA studies ascertain traits on the background of ongo-
ing drug therapy. Therefore, in lieu of statistical models that
consider only the genetic main effects, analyses incorporating
gene-drug interactions may increase the yield for findings of
association.
According to guidelines recommended by the Joint National
Committee on Prevention, Detection, Evaluation, and Treatment
of High BP, thiazide and thiazide-like diuretics should be con-
sidered first-line antihypertensive drug therapy for patients
with uncomplicated HTN in the absence of other “com-
pelling” comorbid indications such as diabetes and heart fail-
ure (Chobanian et al., 2003). This recommendation was based
largely on the results of the Antihypertensive and Lipid-
Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
in which use of a diuretic was associated with reduced inci-
dence of heart failure compared to the angiotensin-converting
enzyme inhibitor and the calcium-channel blocker (ALLHAT
Collaborative Research Group, 2002). However, in addition
to the disparity in the prevalence of HTN, differences in
drug response have also been noted. For example, African-
American race is associated with significantly greater systolic
BP (SBP) and/or diastolic BP (DBP) responses to thiazide
and loop diuretics compared to European-American patients
in small studies (Chapman et al., 2002; Wu et al., 2005).
Population-based differences may be attributable, at least in
part, to differences in the genetic architecture of BP between
world populations. Therefore, current efforts attempting to
increase representation from other continental populations may
improve the generalizability of genetic studies to diverse patient
populations.
Loop diuretics such as furosemide and bumetanide lower
BP by blocking the action of the SLC12A1 (NKCC2) sodium-
potassium-chloride channel in kidney, resulting in decreased
reabsorption of sodium, potassium, and chloride, and hence
water, from the urine. Bartter’s Syndrome Type 1 was identified
by linkage analysis to be the result of homozygous or com-
pound heterozygous non-functional mutations in the SLC12A1
gene; this rare disorder is characterized by neonatal hypoten-
sion, volume depletion, and increased risk for death (Simon
et al., 1996). Loop diuretics also inhibit the SLC12A5 (NKCC1),
a homolog that is more widely expressed in the brain (Kanaka
et al., 2001). The potential for genetic variants to modulate
drug response extends beyond the actual molecular targets
of the drug and may include variants in proteins control-
ling intestinal absorption, enzymatic biotransformation, bind-
ing to carrier proteins, and renal elimination (Vormfelde et al.,
2003).
Here we consider whether SNP-loop diuretic interactions play
a role in the genetic architecture of BP in African- and European-
American families in the HyperGEN study. The identification of
genetic variants that affect drug response could help practition-
ers to individualize medical therapy with the goal of optimiz-
ing benefit and reducing adverse effects both within and across
populations.
MATERIALS AND METHODS
STUDY SAMPLE
HyperGEN is a multicenter family-based study to research the
genetic causes of HTN and related conditions (Williams et al.,
2000). Hypertensive sibships were enrolled from four separate
field centers from 1995 to 2005: Minneapolis, MN; Salt Lake City,
UT; Forsyth County, NC; and Birmingham, AL. The available
dataset was derived from 1258 subjects in 467 African-American
families and 1270 subjects in 299 European-American families.
Subjects with missing covariates (age, sex, and body mass index
[BMI]) and/or drug exposure (loop diuretics) were excluded.
Individuals with HTN onset past age 60 or secondary to pri-
mary kidney disease were also excluded (Williams et al., 2000).
Given loop diuretics are frequently prescribed to control symp-
toms in patients with reduced left ventricular systolic function,
two analysis models were considered. For the primary analysis, we
used the “Continuous-Covariate” model which included left ven-
tricular ejection fraction (LVEF) as a continuous covariate; 1222
subjects in 459 African-American families and 1231 subjects in
299 European-American families were available. To test for a pos-
sible confounding association between the uses of loop diuretics
in subjects with low LVEF, the secondary “All Subjects” model
included all subjects regardless of the availability or value of LVEF;
1249 subjects in 466 African-American families and 1267 subjects
in 299 European-American families were available. Supine BPs
and LVEF were measured as previously described (Williams et al.,
2000; Kizer et al., 2004). The institutional review board at each
field center gave approval for the study protocol and informed
consent procedure.
GENOTYPED AND IMPUTED DATA
Most of the African-American subjects (N = 1083) were geno-
typed using the Affymetrix Genome-wide Human SNP array
6.0 [909,622 SNPs; Birdseed Genotype Calling Algorithm (Korn
et al., 2008)]. The remaining African-American (N = 175) and
all 1270 European-American subjects were genotyped using the
Affymetrix Genome-wide Human SNP array 5.0 (443,816 SNPs;
Bayesian Robust Linear Model with Mahalanobis distance clas-
sifier [BRLMM] calling algorithm). Genomic data was quality
controlled separately by race and by array as follows: samples
were removed for quality-related problems; SNPs were removed if
monomorphic, identified as an Affymetrix “house-keeping” SNP,
missing chromosomal location, or located on a mitochondrial or
sex chromosome; PLINK (Purcell et al., 2007) was used to find
and correct all non-Mendelian inheritance errors (performed in
a dataset integrating both arrays for the AA datasets); and SNPs
with missing rates >5%, minor allele frequency <1%, or Hardy
Weinberg p-value<10−6 were excluded. An account of genotyped
SNPs remaining following quality control is shown in Supplement
Table 1.
Genotype imputation was performed separately within each
race by the HyperGEN Data Coordinating Center using the
post-quality controlled genotype data for HyperGEN African-
American (846,813 genotyped SNPs) and European-American
(358,327 genotyped SNPs) subjects. Data from unrelated African-
American individuals (200 with the lowest GWAS missing rate)
were chosen from a total of 467 African-American HyperGEN
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families to estimate the imputation model parameters. Using
MACH software and the estimated imputation model param-
eters, ∼3.01 million HapMap SNPs (release 22, phasing data,
“revised union” of CEU and YRI populations) were imputed
in the African-American cohort. For association analysis, we
used a dataset of 2,943,641 genotyped and imputed SNPs, after
excluding SNPs that had imputation quality measure (R2) < 0.3,
minor allele frequency <1%, or Hardy Weinberg p-value <10−6.
Genotypes were similarly imputed in the European-American
cohort using ∼2.54 million HapMap SNPs (release 22, phasing
data, CEU population). We used a dataset of 2,367,693 genotyped
and imputed SNPs using the same exclusion criteria. Association
analyses were performed separately using genotyped and imputed
SNPs and then results combined; when both genotyped and
imputed data was available at any locus, the genotyped data
was retained preferentially. Genomic information was obtained
from the National Center for Biotechnology Information human
genome assembly (March 2006, build 36.1, hg18). A locus was
defined as a cluster of SNPs within 100kb of the SNP with the
lowest P-value in the region.
ANALYSIS APPROACH
Population characteristics were expressed as percentages or
mean± standard deviation. The EIGENSOFT package (Patterson
et al., 2006) was used to estimate a set of 10 principal compo-
nents (PCs) for the AA subjects from 382,671 SNPs (representing
the intersection of the Affymetrix Genome-Wide Human SNP
5.0 and 6.0 Array SNPs). The PCs were estimated from unre-
lated subjects chosen from each family; the 10 PC’s were then
predicted for the remaining subjects. Since HyperGEN is a family
study, a linear mixed model with a random polygenic component
was used to account for phenotypic correlations among rela-
tives. We used GenABEL (Aulchenko et al., 2007) and ProbABEL
(Aulchenko et al., 2010) packages, components of the ABEL suite,
and performed a two-step score test approximation, following
the developer’s recommendation for the analysis of family data.
In the first step, GenABEL was used to run a polygenic model,
which provides maximum likelihood estimates (MLEs) of our
covariate effects (e.g., age, age2, age3, sex, BMI, and LVEF), resid-
ual variance, and variance-covariance matrix for the SBP (or
DBP) phenotype. Analyses of the African-American cohort also
included 10 principal components of the GWAS SNPs represent-
ing population substructure as a co-variate to control type I error
rates due to population stratification (Shriner et al., 2011). In
the second step, the score tests for SNP and medication main
effects (assuming an additive model), as well as their interaction
effects, were performed in ProbABEL using the MLE of the other
parameters created from the first step.
MERLIN also internally performs association analysis using
this two-step score approach and provides identical results for
the main effect, but it is more straightforward to use the ABEL
suite for interaction analysis. Because both the ABEL suite and
MERLIN take account for phenotypic correlation across family
members using the kinship matrix, they are more sophisticated
than a mixed effects model with random effect for family related-
ness. For example, in amixedmodel the phenotypic correlation of
half siblings is the same as the correlation of full siblings, whereas
in the ABEL suite the correlation of half siblings is half the cor-
relation of full siblings. The effect of loop diuretics was coded
as dummy variable (0/1), whose main effect was included along
with SNP-drug interaction effect in the association analysis for
SBP and DBP. For each SNP, the interaction effect coefficients
were tested in the presence of the SNP main effect and medica-
tion main effect. The exposure group consisted of subjects taking
loop diuretics, either alone or in combination with other anti-
hypertensive drugs. The comparison group consisted of subjects
not taking loop diuretics, although other antihypertensive drugs
were permitted. A Wald test was computed to determine the sig-
nificance using chi-squared statistics with one degree of freedom.
The “Continuous-Covariate” model included LVEF as a continu-
ous covariate. Similarly, the “All Subjects” model was performed
using the entire cohort without consideration of the availability
or value of LVEF.
Quantile-quantile (QQ) plots were performed for each
race/trait combination to assess deviation from the normal dis-
tribution; the genomic control inflation (lambda) factor was
calculated. Manhattan plots were generated in SAS (Version 9.3,
SAS Institute, Cary, North Carolina, USA), with the y-axis indi-
cating −log10(P) values and the x-axis plots the physical position
of the SNPs in genomic order, by chromosome and chromo-
some position. Plots were created for the SNP main effect in the
presence of the medication main effect and interaction effect, as
well as for the interaction effect in the presence of the SNP and
medication main effects. Regional association plots were gener-
ated to highlight chromosomal regions with a clustering of SNPs
with suggestive association using LocusZoom software, available
at http://csg.sph.umich.edu/locuszoom/. The linkage disequilib-
rium (LD) (r2) was calculated from the hg18/HapMap Phase II
YRI population for AA and hg18/HapMap Phase II CEU popula-
tion for EA. SNPs (circles) are colored according to their level of
LD of each SNP with the index SNP (purple diamond) selected
as the most significant SNP in the region. Gray points are SNPs
without available LD information.
RESULTS
Compared to the European-American cohort, the African-
American cohort tended to be older and more predominantly
female, with higher BMI, SBP, and DBP. Loop diuretics were used
by 96 (7.9%) African-American and by 48 (3.9%) EA subjects
(Table 1). LVEF was missing from 27 AA and 36 EA; these indi-
viduals were excluded from the “Continuous-Covariate” models
but included in the “All Subjects” models. The prevalence of low
EF (LVEF ≤45%) was low (3.8% in AA, and 3.2% in EA).
The QQ plots showed evidence of inflation, in particular for
the loop-SNP interaction terms for SBP analyses; Supplement
Figure 1 shows the unadjusted P-values (black circles) and P-
values adjusted for the genetic inflation factor lambda (genomic
control, blue crosses). Association analysis results are shown in
Figures 1–4. Manhattan plots show the adjusted −log10(P) val-
ues for both SBP (Figures 1 and 3) and DBP (Figures 2 and 4)
for both races. In each figure, the top Manhattan plot shows
the SNP main effect in the presence of the SNP-loop diuretic
interaction effect, and the bottom Manhattan plot shows the
SNP-loop diuretic interaction in the presence of the SNP main
www.frontiersin.org December 2013 | Volume 4 | Article 304 | 3
de las Fuentes et al. SNP-loop diuretic interactions in hypertension
Table 1 | Descriptive statistics of the study population.∗
Characteristics African- European-
American Cohort American Cohort
Sample size, n 1222 1231
Male, n (%) 398 (33%) 613 (50%)
Loop diuretic use, n (%) 96 (7.9 %) 48 (3.9%)
Age, years 45 ± 13 50 ± 14
Body mass index, kg/m2 32.4 ± 7.9 29.3 ± 6.0
Systolic blood pressure, mm Hg 129 ± 22 123 ± 19
Diastolic blood pressure, mm Hg 74 ± 12 71 ± 10
Left ventricular ejection fraction, % 61 ± 8 62 ± 8
% EF ≥ 45 1175 (96.2%) 1192 (96.8%)
*For “Continuous-Covariate” model. % EF ≥ 45, percent with left ventricular
ejection fraction ≥45%.
FIGURE 1 | Association Results for SBP for African Americans: Main
and Interaction Effects with Loop Diuretics.
FIGURE 2 | Association Results for DBP for African Americans: Main
and Interaction Effects with Loop Diuretics.
effect. SNPs selected for regional plotting were chosen based on
the strong clustering on the Manhattan plots, as well as for the
number of SNPs in that region that showed promising levels of
significance. Regional plots are shown in Figures 5–7. The top-
scoring SNPs for association with gene-medication interactions
in BP are shown for AA in Table 2 (P < 1 · 10−6) and for EA in
Table 3 (P < 1 · 10−5). Online Supplement Tables 2–3 show the
100 most highly ranked SNP-loop diuretic interactions per race.
Supplement Table 4 compares these top scoring SNPs from each
cohort and phenotype top allow cross-race comparisons.
FIGURE 3 | Association Results for SBP for European Americans: Main
and Interaction Effects with Loop Diuretics.
FIGURE 4 | Association Results for DBP for European Americans: Main
and Interaction Effects with Loop Diuretics.
RACE-SPECIFIC ASSOCIATION WITH SBP AND DBP
For the African-American cohort, there were 14 SNPs in 7 loci
with suggestive association with SBP (P < 1 · 10−6; Figure 1);
the SNP with the most promising P-value was rs7702688 (P =
2.39 · 10−7) which lies in a relative gene desert ∼0.77Mb down-
stream of the NUDT12 gene and is in high pairwise LD with
many other SNPs with more modest association located at that
locus. Other promising SNPs with suggestive associations with
SBP in AA include rs1633278 (P = 5.59 · 10−7) near PYHIN1 on
chromosome 1, rs2729258 (P = 5.71 · 10−7) on chromosome 3
which lies ∼0.18Mb downstream of the CHL1 gene, rs11744176
(P = 6.56 · 10−7) which is intragenic to GRIA1 on chromosome
5. Another cluster of SNPs on chromosome 10 with more modest
associations with SBP in AA are notable because they are within
CACNB2 (rs16916928; P = 1.81 · 10−6), a gene previously asso-
ciated with cardiovascular traits (rs16916928; P = 1.81 · 10−6).
There were 6 SNPs in 2 loci with suggestive association with DBP
(P < 1 · 10−6; Figure 2). The SNP with the lowest P-value for
DBP in AA was rs2811944 (P = 1.53 · 10−7), located on chro-
mosome 1 adjacent to the ID3 gene. Supplement Table 2 shows
evidence of strong clustering on chromosomes 3 and 5 (with
multiple SNPs in strong LD).
For the European-American cohort, a more permissive P-
value <1 · 10−5 was considered given the relatively lower power
due to the fewer number of subjects exposed to loop diuretics
(3.9% vs. 7.9% in AA). There was one SNP with a promising asso-
ciation with SBP in EA (rs3020401, P = 9.51 · 10−6) in ESR1 on
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FIGURE 5 | Regional Plot Results for SBP for African Americans.
chromosome 6 (Figure 3). A greater number of SNPs, 49 SNPs in
5 loci, showed suggestive associations with DBP in the European-
American cohort (P < 1 · 10−5; Figure 4). Among these SNPs
was rs3790481 (P = 2.93 · 10−6) in DEPDC1 on chromosome 1,
and rs6012061 (P = 4.06 · 10−6) residing in an intron in EYA2 on
chromosome 20.
No SNP showing strong interaction effect also demonstrated
suggestive main effects. It is also notable that a top-100 associated
SNP in one cohort/phenotype combination often showed weak-
ened association for the other phenotype in the same cohort (see
Supplement Table 4). Corroborative evidence was less commonly
noted across race groups. A difference in minor allele frequencies
among top SNPs may explain, at least in part, the difference in
association across races for some SNPs. For example, rs2729258
on chromosome 3 which has an allele frequency of 0.43 in AA
(where P = 5.71 · 10−7 with SBP), has a frequency of only 0.06 in
EA where it showed no association (P = 0.64).
FOLLOW-UP SEX-STRATIFIED ANALYSES
Since genetic variants in ESR1 have been previously noted to
affect BP in a sex-specific manner, the “continuous-covariate”
model was repeated in analyses stratified by sex in only the
European-American cohort (males: n = 613; females: n = 618),
limiting the regions of interest to the 1Mb regions surrounding
rs3020401. The resulting analyses showed that the association
for SBP was greater in European-American men (unadjusted
P = 4.1 · 10−7 for rs3020401) than women (top scoring SNP in
region with unadjusted P = 2.3 · 10−4). The association for DBP
in European-American men and women was weaker (unadjusted
P < 8.2 · 10−4 for both).
COMPARISONWITH ALL SUBJECTS MODEL
Secondary analyses were performed in order to test for a possi-
ble confounding association between the uses of loop diuretics in
subjects with low LVEF. In addition to the primary “Continuous-
Covariate” models that analyzed data from subjects with available
LVEF as a continuous trait, “All Subjects” models were also
performed using the entire cohort (AA 1249 and EA 1267) with-
out consideration of availability or value of LVEF. Compared
to our primary results, there were few differences noted in the
Manhattan and regional plots for the “All Subjects” analyses in
African- and European-Americans cohorts for either SBP or DBP.
In general, the overall clustering and trends of association were
preserved even if the specific top-scoring signals varied somewhat
at any particular locus. In the “All Subjects” model, there were 6
SNPs with suggestive associations clustered on chromosome 17
for SBP in EA that were not seen in the “Continuous-Covariate”
model. This locus is 0.15Mb upstream of the CA10 gene which
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FIGURE 6 | Regional Plot Results for DBP for European Americans, SBP and DBP for European Americans.
encodes a carbonic anhydrase ion channel, the target for a weak
diuretic that is more commonly used today to treat glaucoma and
altitude sickness.
DISCUSSION
The relationship between BP and the risk of cardiovascular dis-
easemortality is continuous, consistent, and independent of other
risk factors (Lewington et al., 2002). Epidemiologic studies have
shown that even modest control of BP on the range of 2–5mmHg
reduction can result in a significant decrease in cardiovascular dis-
ease mortality (Cook et al., 1995; Sacks et al., 2001; Whelton et al.,
2002). Therefore the identification of SNP-drug interactions for
HTN-related traits may identify optimal treatment strategies for
patients and regulatory pathways that can be exploited for future
drug development and/or personalized treatment of HTN in the
general population.
Despite recent GWA studies of HTN-related traits that have
included massive sample sizes,<3% of the inter-individual varia-
tion in BP has been explained by known (common) variants (Levy
et al., 2009; Newton-Cheh et al., 2009; International Consortium
for BP GWAS et al., 2011). Since blood pressure-related traits
are typically measured during ongoing drug therapy, considera-
tion of SNP-drug interactions may identify additional target loci
associated with BP. Herein we report findings from an analysis
of GWA data for SNP-loop diuretic medication interactions
in systolic and diastolic BPs in the biracial HyperGEN study
cohort. We have identified several promising SNPs for both SBP
and DBP in the African- and European-American cohorts. It
is noteworthy that among the SNPs with the most suggestive
interaction effects, none showed equally compelling main effects.
It is also notable that SNPs with strong interaction effects in
one race cohort rarely showed association in the other. Thus,
although none of the reported associations surpassed the strin-
gent Bonferroni-adjusted genome-wide significance threshold
(P < 5 · 10−8), these biologically plausible results nonetheless
highlight the importance of evaluating related phenotypes in
diverse racial/ethnic cohorts as a strategy to increase the yield
for loci relevant to BP regulation and/or antihypertensive drug
response and to broaden the generalizability of future therapeutic
approaches to multiple patient populations.
Among genes with known associations with cardiovascular
traits is CACNB2 (rs16916928; P = 1.81 · 10−6) which has drug-
SNP interaction effect on SBP in the African-American cohort.
The CACNB2 gene encodes the β2 subunit of the L-type voltage-
gated calcium channel that is widely expressed in cardiovascular
tissue. A non-synonymous variant in CACNB2 has been shown
to be responsible for Brugada’s syndrome, a heritable sudden car-
diac death syndrome (Antzelevitch et al., 2007). This calcium
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channel is also the target for the anti-hypertensive calcium chan-
nel blocker drugs. Variants in CACNB2 have been associated with
HTN traits in numerous, including multiracial, studies (Levy
et al., 2009; Ho et al., 2011; International Consortium for BP
GWAS et al., 2011; Kato et al., 2011; Lin et al., 2011; Wain
et al., 2011). CACNB2 SNPs were genotyped in the INternational
VErapamil SR-Trandolapril STudy-GENEtic substudy (INVEST-
GENES), a outcomes study including 5598 hypertensive patients
with coronary artery disease who were randomized to either a β-
blocker or a calcium channel blocker (Niu et al., 2010). There was
a greater risk of adverse outcomes in patients with a rare promoter
genotype (G/G, rs2357928) when randomized to the calcium
channel blocker vs. the β-blocker, a finding that was consistent in
European-, African- and Hispanic-American cohorts. Functional
assays showed a significant increase in promoter activity for the
rare allele. Since HTN is strongly tied to cardiovascular outcomes,
these findings add further evidence of physiologic importance of
this gene to cardiovascular traits. In the INVEST-GENES study,
only a borderline main effect was detected for rs2357928 in AA;
as in our study, rs16916928 was only associated with BP in AA
when considered in the context of loop diuretic therapy (Niu
et al., 2010). Notably, loop diuretics, by inhibiting the sodium-
potassium-chloride channel in the kidney, also increase urinary
calcium excretion (Rejnmark et al., 2003); thus, there is bio-
logic plausibility linking diuretic use with SNPs in CACNB2 in
modulating BP regulation.
Among the SNPs with suggestive association for SBP in the
European-American cohort was rs3020401 (P-value = 9.51 ·
10−6), which is within the ESR1, a gene that encodes the estrogen
receptor α. Aside from well-described involvement in gyneco-
logic malignancies and osteoporosis, ESR1 has also been impli-
cated in mostly candidate gene studies of myocardial infarction,
ischemic heart disease risk, in-stent restenosis, sudden cardiac
death and age-related changes in left ventricular structure, often
with disparate associations in men and women (Ferrero et al.,
2003; Schuit et al., 2004; Peter et al., 2007; Aouizerat et al.,
2011). There are also examples of variants in ESR1 interact-
ing with hormone replacement therapy to alter high-density
lipoprotein levels and atherosclerosis severity (Herrington et al.,
2002; Koivu et al., 2003). A handful of candidate-gene stud-
ies have associated genetic variants in ESR1 with BP-related
traits. The Victorian Family Heart Study (Ellis et al., 2004) and
Framingham Offspring Study (Peter et al., 2005) both identi-
fied ESR1 variants with sex-specific associations with SBP and
DBP, respectively, in EA. Furthermore, the GenSalt study, which
investigated the genetic determinants of BP response to low-
and high-salt diet interventions in Han Chinese, also identi-
fied ESR1 variants associated with DBP in men, but not women
(Kelly et al., 2013). Therefore, in order to explore the possibil-
ity of a sex-specific interaction between SNPs in ESR1 and loop
diuretics, the current study performed additional analyses strat-
ifying the European-American cohort by sex. The associations
detected, while less significant due to the smaller sample size,
were strongest in men. It is notable that mean ages of the women
in both the Victorian Family Heart Study and HyperGEN were
54 and 50 years, respectively; thus, we are not able to determine
whether the association between SBP and ESR1would be stronger
among post-menopausal (estrogen-deficient) women. Although
the mechanisms remain unclear, our results suggest that loop
diuretics interact with variants in the ESR1 gene to modulate SBP
and that these effects may be further influenced by sex and/or
estrogen status.
Among suggestive SNPs, other genes identified have less estab-
lished roles in cardiovascular disease. The top-scoring drug-SNP
interaction for SBP in the African-American cohort is located
on chromosome 5 (rs7702688; P = 2.39 · 10−7) in a relative gene
desert ∼0.77Mb downstream of the NUDT12 gene. NUDT12 is a
Nudix hydrolase, a class of enzymes that regulates levels of circu-
lating diadenosine phosphates (Abdelraheim et al., 2003) which
have been shown to have vasoactive properties (Schluter et al.,
1994). SNPs in this region have shownmarginal associations with
BP traits (Gene [database on the Internet] et al., 2013). Also
among the more novel findings of this study is an association
for SBP in the African-American cohort with SNPs intragenic to
GRIA1 (rs11744176; P = 6.56 · 10−7) which encodes the alpha-
amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)-
type glutamate receptor, an ion channel receptor. The binding
of the neurotransmitter L-glutamate induces a conformational
change allowing the passage of sodium and calcium through the
channel, causing depolarization of the neuron. While GWA stud-
ies have detected borderline associations with longevity, healthy
aging, and sudden cardiac death (Aouizerat et al., 2011; Walter
et al., 2011), GRIA1 has not been identified in other GWA studies
of HTN or BP. However, the AMPA receptor has been implicated
in the control of fluid ingestion (De Gobbi et al., 2009), a deter-
minant of BP regulation. Perhaps more intriguing, both loop and
thiazide diuretics have been shown to potentiate AMPA receptor-
dependent ion channel activity by reducing intracellular chloride
concentrations in neurons, favoring depolarization (Yamada and
Tang, 1993; Sipila et al., 2009). AMPA activation in the hypothala-
mus increases vasopressin release, a hormone which causes both
water retention and vasoconstriction. Thus, there is biologic plau-
sibility that genetic variants in the GRIA1 gene may modulate the
BP response to diuretics (Sladek et al., 1998).
Another interesting finding was identified only in analyses that
included all subjects regardless of the availability of the LVEF.
SNPs in CA10 interacted with loop diuretics to modulate SBP
in the European-American cohort. Carbonic anhydrases, such as
that encoded by CA10, function to buffer metabolic sources of
acid through reabsorption of bicarbonate, along with sodium and
chloride, from the urine (Epstein and Grant, 1977). Synergism
between loop diuretics and carbonic anhydrase inhibitors has
prompted the use of combination therapy in patients resistant to
diuresis (Ellison, 1991). In addition to volume overload, patients
with heart failure may experience metabolic acidosis which could
favor increased activity of carbonic anhydrases (Reddy et al.,
1988); therefore genetic variants that alter the activity of these
ion channels may in turn modulate the effectiveness of the loop
diuretics to excrete sodium and hence control BP.
SNPs in SPATS2L (spermatogenesis-associated serine-rich
protein 2-like) have also been associated with both SBP and DBP
in a Korean cohort (Hong et al., 2010, 2011). Likewise, SNPs in
EYA2 (eyes absent homolog 2) have been associated with HTN in
a Japanese cohort (Kato et al., 2008). Although the mechanisms
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by which these genes are associated with BP regulation remains
elusive, these findings are consistent with the present study where
SNPs in both SPATS2L and EYA2 showed suggestive interaction
associations with loop diuretics for DBP in AA. The top-scoring
SNP for DBP in AA is intragenic to the ID3 (inhibitor of differen-
tiation 3) gene. This gene encodes a transcription factor that has
been found to be protective against atherosclerosis (Doran et al.,
2010; Owens et al., 2010); a common loss-of-function SNP in the
human ID3 gene has been linked increased carotid intima-media
thickness (Doran et al., 2010), an intermediate trait associated
with a variety of cardiovascular outcomes (Lorenz et al., 2006).
CHL1, a gene associated in this study with SBP in AA, is a known
tumor suppressor gene; CHL1 SNPs have been shown to asso-
ciate with LDL in interactionmodels with statin use (Barber et al.,
2010).
Given the small proportion of subjects taking loop diuretics
in the AA, and in particular the EA cohorts, there was lit-
tle expectation of finding genome-wide significant interactions
due to limited power. Nonetheless, these analyses have identified
several genes with promising associations notable for plausible
biologic contributions to BP regulation and/or antihypertensive
drug response. Given that more permissive thresholds were used
to identify suggestive genes in the present study, additional studies
are necessary to confirm the findings and to determine potential
mechanisms for a role in BP regulation. Our findings may also be
limited by not accounting for the use of non-loop diuretics in the
comparison group or for the use of combination antihypertensive
therapies in the exposure group. This may have further reduced
the power. It is also unclear to what degree lack of information
on dosage, duration of therapy, and/or medication compliance of
loop diuretic therapy may have influenced our results. While not
adjusting for LVEF strengthened the association of SNPs in CA10
which were not identified in the “Continuous-Covariate” model,
the prevalence of subjects with an LVEF <45% was low (77 of
1222 African-American and 39 of 1231 European-American sub-
jects), thereby limiting the strength of any conclusions from these
analyses. However, since the majority of peaks were common
to both the “Continuous-Covariate” and “All Subjects” models,
associated loci are unlikely to be the result of bias introduced by
the correlation between loop diuretic use and left ventricular sys-
tolic dysfunction. In summary, genome-wide interaction analyses
that consider the impact of loop diuretic use, including SNP-loop
interactions, on BP traits may provide a prioritized set of SNPs
and candidate genes worthy of replication and validation in stud-
ies of HTN. Studies in more diversified population samples may
help identify previously missed variants. In the meantime, these
findings make an important contribution to the body of literature
aimed at eliminating race disparities through tailored medical
therapies.
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